Walter Elisei

Plain English
This study looked at ways to prevent acute diverticulitis, a painful condition that affects the colon, in nearly 2,000 patients with newly diagnosed diverticular disease. Researchers followed the patients for three years and found that those on a high-fiber diet had a 5.9% risk of developing the condition, while patients taking mesalamine faced a 9.5% risk, and those on a combination of mesalamine and rifaximin had a 17.1% risk. Notably, mesalamine significantly reduced the risk of diverticulitis in patients with more severe inflammation, showing a 77% to 84% lower risk compared to other treatments. Who this helps: This research benefits patients suffering from diverticular disease by helping doctors choose better treatments to prevent diverticulitis.

Plain English
This study looked at the impact of biosimilars, a type of medication, on the treatment costs for inflammatory bowel diseases (IBD) like Crohn's disease and ulcerative colitis in Italy. Researchers found that while the number of people with these diseases increased significantly—from 146.6 to 203.6 cases of Crohn's disease per 100,000 people, and from 303.2 to 408.3 for ulcerative colitis—treatment costs for advanced therapies dropped by nearly 21%, from about €1.48 million to €1.17 million. This is important because it shows that more people are receiving effective treatment for IBD while overall costs are decreasing, largely due to the use of biosimilars that are more affordable than original biologics. Who this helps: This benefits patients with inflammatory bowel diseases by providing more affordable treatment options.

Plain English
This study examined whether adding 5-aminosalicylic acid (5-ASA) affects the effectiveness of Janus kinase inhibitors (JAKi) in treating ulcerative colitis (UC). Researchers looked at 633 patients and found that after 48 weeks, 81.3% of those taking both JAKi and 5-ASA achieved remission, compared to 77.0% of those who only received JAKi. The presence of 5-ASA did not significantly change the chances of reaching remission. Who this helps: This information benefits doctors and patients with ulcerative colitis by clarifying treatment options.

Plain English
This study looked at how a special mixture of bacteria and fiber (called a symbiotic) affects patients with moderate to severe diverticular disease, a condition related to the colon. Researchers found that this mixture significantly reduced abdominal pain in patients with moderate disease (DICA 2) and also showed some improvement in those with severe disease (DICA 3), with scores dropping from 6 to 4 on a pain scale for DICA 2 patients. The findings suggest that this treatment could be an effective option for managing moderate diverticular disease, potentially allowing patients to feel better without needing extra treatment. Who this helps: This helps patients with moderate diverticular disease.

Plain English
This study looked at how changes in bowel movements, like constipation and diarrhea, relate to the severity of diverticular disease (DD) and the risk of acute diverticulitis, a serious complication. Researchers studied 871 patients, finding that 24% had significant constipation and 23% had significant diarrhea. They discovered that worse constipation or diarrhea scores were linked to more severe DD and increased risk of acute diverticulitis, meaning a 1-point increase in bowel issue scores raised the risk by 15% for constipation and 14% for diarrhea. Who this helps: This benefits patients with diverticular disease by helping them understand their symptoms and manage their risk for complications.

Plain English
Researchers studied how many patients with inflammatory bowel diseases (IBD) moved from receiving their medication vedolizumab intravenously (IV) to taking it under the skin (subcutaneously, or SC). Out of 238 patients who were asked to switch, only 9 (or about 3.78%) chose to do so, even though those who switched successfully maintained their health without any side effects. This is significant because it shows that while SC administration can be safe and effective, most patients prefer to stick with IV treatment when they are feeling well. Who this helps: This helps patients with IBD who are currently using IV vedolizumab.

Plain English
This study looked at a combination of ingredients, including inulin, probiotics, and several vitamins, to see if they could help patients with mild-to-moderate ulcerative colitis (UC). Researchers found that after 8 weeks, about 52% of the 17 patients showed improvement, increasing to 64% at 16 weeks. Additionally, a significant reduction in a specific marker for inflammation in the stool was observed after 8 weeks. This matters because it indicates that this combination might help manage UC symptoms effectively without causing any harm. Who this helps: Patients with mild-to-moderate ulcerative colitis.

Plain English
This study examined the effectiveness and safety of the drug filgotinib for treating ulcerative colitis (UC) in patients who had already tried other treatments. Out of 102 patients followed for about six months, 46% achieved clinical remission by the end of the study, and those who started filgotinib first had a higher success rate compared to those on second or third lines of therapy. This research is important as it shows that using filgotinib early in treatment can lead to better outcomes with relatively few adverse effects. Who this helps: This benefits patients with ulcerative colitis, particularly those looking for effective treatment options.

Plain English
This study looked at whether a specific probiotic called Lactobacillus paracasei CNCM I 1572 could help prevent acute diverticulitis (a painful inflammation of the colon) in patients who have mild diverticular disease. Out of 105 participants, only 1 patient taking the probiotic developed acute diverticulitis, compared to 6 patients in the placebo group, showing that the probiotic reduces the risk significantly (p=0.036). This discovery offers a potential new way to prevent complications in patients with diverticular disease. Who this helps: This benefits patients suffering from diverticular disease and their healthcare providers.

Plain English
This study looked at how male and female patients with ulcerative colitis respond to three different treatments: vedolizumab, ustekinumab, and tofacitinib, over a period of 48 weeks. It found that males treated with ustekinumab had better rates of clinical and steroid-free remission at 24 weeks, while females on tofacitinib showed better remission rates at 8 weeks. These findings are important because they can help doctors tailor treatments based on a patient’s sex, improving outcomes for both men and women. Who this helps: This helps patients with ulcerative colitis and their doctors in choosing more effective treatments.

Plain English
This study looks at diverticular disease, a common condition where pouches form in the colon, affecting many people in developed countries. It found that while 20-25% of those with diverticulosis show symptoms, high fiber diets can reduce risk, while smoking and obesity increase it. The report provides clear recommendations for managing this condition, such as using dietary changes instead of routine antibiotics and focusing on individual patient needs for surgery. Who this helps: This helps patients with diverticular disease and their doctors.

Plain English
This study looked at the effectiveness and safety of Upadacitinib (UPA) in treating patients with ulcerative colitis who did not respond to other treatments. Among 202 patients, 45.5% achieved clinical remission at 8 weeks, and by the end of the study, 60.2% were in remission, with 84.6% showing healing in their intestinal lining. The research confirms that UPA is a valuable option for patients with difficult-to-treat ulcerative colitis, with a low rate of serious side effects. Who this helps: Patients with ulcerative colitis who have not had success with other treatments.

Plain English
This study looked at the drug ustekinumab (UST) to see how well it works and how safe it is for patients with ulcerative colitis (UC). Researchers followed 256 patients and found that by 24 weeks, 27.6% of them achieved clinical remission, and 61.8% showed a clinical response. The study also noted that only a small number of patients experienced adverse effects (2.3%), which indicates that UST can be a safe and effective option for treating UC. Who this helps: Patients suffering from ulcerative colitis.

Plain English
This study examined how a new plan, called the Diagnostic and Therapeutic Assistance Pathway (PDTA), changed how patients with acute diverticulitis (AD) are treated in the emergency room (ER). Between 2021 and 2022, there were 290 ER admissions for AD, compared to 240 per year from 2015 to 2019. The new plan led to shorter ER stays for over 24 hours and reduced hospital stays, with more patients receiving medical treatment instead of surgery. Who this helps: This benefits patients with acute diverticulitis by offering more effective treatment options and shorter hospital visits.

Plain English
This study looked at how well the drug ustekinumab (UST) works for patients with Crohn's disease over a long period. Among 562 patients, 80% were in clinical remission after two years, and an impressive 95.4% were in remission after one year of treatment. Only a small number needed surgery (2.1%) or faced other treatment adjustments, showing that UST is generally safe and effective for long-term use. Who this helps: This benefits patients with moderate to severe Crohn's disease seeking effective long-term treatment options.

Plain English
The study looked at the levels of a specific type of bacteria in patients with symptomatic uncomplicated diverticular disease (SUDD) compared to those with asymptomatic diverticulosis and healthy individuals. Researchers found no significant differences in the amount of this bacteria among the three groups. This matters because it suggests that the bacterial levels in people with SUDD are similar to those in healthy individuals and may be different from those in people with inflammatory bowel disease. Who this helps: This research helps doctors better understand the gut health of patients with diverticular disease.

Plain English
This study looked at how the COVID-19 pandemic affected outpatient gastrointestinal (G.I.) endoscopy procedures in the Apulia region of southern Italy from 2019 to 2022. Researchers found that the number of procedures sharply dropped by about 44% in 2020 but then slightly increased over the next two years, yet still remained lower than pre-pandemic levels. The appropriateness of these procedures improved during 2020, with a rate of 81%, but fell to 69% by 2022, indicating the need for more education and training to ensure these services are used effectively. Who this helps: This benefits patients needing G.I. procedures and healthcare providers who perform these services.

Plain English
This study looked at patients taking proton pump inhibitors (PPIs), a type of medication used to reduce stomach acid, to see how often they develop a condition called small intestinal bacterial overgrowth (SIBO) and produce a specific gas, methane (CH4). Among 125 patients on PPIs, 30.4% had SIBO and a surprising 61.6% produced methane. After treatment with the antibiotic rifaximin, about 68% of the SIBO patients showed improvement, which highlights rifaximin’s potential as a helpful option for managing SIBO caused by long-term PPI use. Who this helps: Patients on proton pump inhibitors experiencing digestive issues.

Plain English
This study looked at how well the medication tofacitinib works for patients with ulcerative colitis in real-life settings in Italy. Researchers found that after 24 weeks, about 45% of patients using tofacitinib achieved clinical remission, and it worked better when used as an initial treatment rather than later, with a significant difference in success rates (36.7% at 8 weeks and 45.2% at 24 weeks). These results are important because they show that using tofacitinib early can lead to better outcomes for patients with this condition. Who this helps: Patients with ulcerative colitis looking for effective treatment options.

Plain English
This study looked at how common a condition called segmental colitis associated with diverticulosis (SCAD) is among people newly diagnosed with diverticulosis. Out of 2,215 patients, 44 were found to have SCAD, which means it occurs in about 2% of these cases. Those with specific types of SCAD experienced worse symptoms and were less likely to fully recover compared to others. Who this helps: This information is useful for doctors treating patients with diverticulosis to better understand and manage the potential complications.

Plain English
This study looked at how well two assessment methods, DICA and CODA, can predict complications in patients with diverticular disease, and whether measuring fecal calprotectin (FC) can improve those predictions. They followed 871 patients and found that higher levels of FC were linked to a greater risk of acute diverticulitis, specifically with a risk increase of 3.29 times for each tenfold increase in FC concentration within the first three years. While FC can help assess immediate risk of complications, the study suggests using DICA and CODA alone for longer-term treatment strategies, as they were more accurate overall. Who this helps: This research helps doctors better assess and manage patients with diverticular disease.

Plain English
This study looked at four adalimumab biosimilars—SB5, ABP501, GP2017, and MSB11022—in treating patients with inflammatory bowel diseases (IBD). Researchers found that 79.6% of new patients achieved clinical remission with these medications, and 81% of patients switching from the original drug maintained their remission. The study showed that all four biosimilars are effective and safe, with only 6.7% of patients experiencing adverse effects, and there were no significant differences between the biosimilars. Who this helps: This benefits patients with inflammatory bowel diseases, providing them with effective, lower-cost treatment options.

Plain English
This study looked at how effective and safe the medication vedolizumab (VDZ) is for patients with ulcerative colitis (UC) compared to those with Crohn's disease (CD). Researchers followed 729 patients for about 18 months and found that at six months, 66.9% of all patients achieved clinical remission, with 74.4% in the CD group and 62.9% in the UC group. Over the entire follow-up period, both groups showed similar long-term remission rates of 81.5%. Understanding these differences is important for doctors to make better treatment decisions for their patients. Who this helps: This helps patients with ulcerative colitis and Crohn's disease, as well as their doctors.

Plain English
This study looked at a natural supplement called Enteroflegin to see how well it works for patients with symptomatic uncomplicated diverticular disease (SUDD), which causes issues like abdominal pain without serious inflammation. Among 350 patients, Enteroflegin helped about 17.6% achieve full symptom relief after six months, while about 85% felt their symptoms improved. Additionally, there were very few cases of worsening symptoms or acute diverticulitis, showing the supplement's promise in managing this condition. Who this helps: This helps patients suffering from SUDD.

Plain English
This study looked at how well a cheaper version of the drug adalimumab (called GP2017) works compared to the original version (Humira) in treating patients with inflammatory bowel disease (IBD). Out of 134 patients treated, 82.3% using GP2017 and 75% using the original drug achieved remission after about a year, showing no significant difference in effectiveness. This matters because it supports using GP2017 as a cost-effective option for patients without compromising treatment outcomes. Who this helps: Patients with inflammatory bowel disease.

Plain English
This study examined the characteristics and health issues of adults with ulcerative colitis (UC) in Sardinia, Italy, by looking at data from 442 patients. The researchers found that patients were typically diagnosed at around 39 years old, with some developing serious complications like cancer—fourteen had cancers outside the colon while only two had colorectal cancer. Understanding these findings helps to better recognize how UC affects people in this region, paving the way for improved treatment and care. Who this helps: This helps patients with ulcerative colitis and their healthcare providers.

Plain English
This study looked at two biosimilar medications, CT-P13 and SB2, used to treat inflammatory bowel diseases (IBD) in patients in Italy. Out of 380 patients, about 67.5% of those with Ulcerative Colitis and 89.6% of those with Crohn's Disease reached remission, with no significant differences between the two treatments. The findings indicate that both biosimilars are effective and safe for managing IBD. Who this helps: This benefits patients with inflammatory bowel diseases.

Plain English
This study looked at how common celiac disease (CD) is among patients in family medicine in Rome, Italy, and whether their diagnoses were accurate. Out of over 22,000 patients, only 91 (0.41%) had CD, with just 60 properly coded in the health system. Many diagnosed patients weren't following the recommended gluten-free diet, indicating that some may not truly meet the criteria for the disease, which is important for ensuring the right treatments and health advice are given. Who this helps: This helps doctors make better diagnoses for patients who might have celiac disease.

Plain English
This study analyzed how well two systems—DICA and CODA—can predict complications for patients with diverticulosis, a condition affecting the intestine. It involved over 2,200 patients from various centers in Europe and South America. The findings showed that patients with higher DICA scores faced increased risks: for those with a DICA score of 3, the chance of needing surgery was 11% over three years, while it was just 0.15% for those with a score of 1. Understanding these scores is important because they help doctors identify which patients might face more severe complications, informing treatment decisions. Who this helps: This benefits patients with diverticulosis and their doctors.

Plain English
This study looked at how well four different versions of the drug adalimumab, called biosimilars, work for patients with inflammatory bowel disease after they switched from the original adalimumab for non-medical reasons. Out of 153 patients, 81% maintained their clinical improvement after about a year, but patients with ulcerative colitis (UC) struggled more, with 39% losing their improvement compared to 15% of those with Crohn's disease (CD). The findings indicate that while the different biosimilars appear equally effective and safe overall, we need to be cautious with UC patients when making such switches. Who this helps: This information benefits patients with inflammatory bowel disease and their doctors.

Plain English
This study looked at 185 patients with symptomatic uncomplicated diverticular disease (SUDD) over an average of 156 months to understand how their symptoms and quality of life changed over time. The researchers found that 7.6% of patients experienced acute diverticulitis, with a small number needing surgery or dying from complications. Overall, the patients' symptoms and quality of life scores remained mostly unchanged during the follow-up period, highlighting that SUDD can significantly impact patients' lives long-term and that acute complications can arise. Who this helps: This helps patients with SUDD and their doctors understand the potential risks and long-term impact of the disease.

Plain English
This study looked at how well Ustekinumab (UST) works for patients with Crohn's disease who have not responded to other treatments. Out of 194 patients, 75% reached clinical remission within 12 weeks, and after 6 months, about 70% maintained that remission. The findings are important because they show that UST can be an effective and safe option for patients who did not get better with previous biologic therapies. Who this helps: This helps Crohn's disease patients who have exhausted other treatment options.

Plain English
This study looked at how well a treatment called adalimumab (ADA) helps patients with ulcerative colitis (UC) not just feel better, but also improve at the microscopic level, which is known as histological remission (HR). Researchers followed 22 patients in deep remission for about 28 months and found that at the start, 68% had some inflammation, but by the end, only 18% showed signs of inflammation. This is important because it shows that while patients may feel better on ADA, achieving complete healing at the microscopic level takes longer than expected. Who this helps: This helps UC patients looking for deeper healing while on adalimumab.

Plain English
This study looked at how well two medications, infliximab and adalimumab, work for patients with Crohn's disease and ulcerative colitis over a long period. It included 712 patients and found that after a few years, 75% of those on adalimumab and 72.5% on infliximab with Crohn's disease were still in remission. For ulcerative colitis, 50% of adalimumab patients stayed in remission compared to 65.8% on infliximab. Importantly, adalimumab had fewer side effects (6.2%) than infliximab (16.6%). Who this helps: This research benefits patients with inflammatory bowel diseases by providing information on the effectiveness and safety of their treatment options.

Plain English
This study looked at a new natural treatment for functional dyspepsia, a digestive problem affecting about 10% of people. Researchers tested a ginger and thyme-based supplement on 272 patients over three months and found that it significantly improved symptoms like stomach pain and bloating. After treatment ended, patients still showed symptom improvement, indicating that this formulation could be a useful option when doctors want to avoid traditional medications. Who this helps: Patients suffering from functional dyspepsia who prefer natural treatment options.

Plain English
This study looked at 28 patients who were diagnosed with Laryngopharyngeal Reflux (LPR) but did not improve with Proton Pump Inhibitors (PPIs), which are commonly used for treating Gastroesophageal Reflux Disease (GERD). The researchers found that only 7.14% had signs of GERD and nearly 43% of the patients had no other identified health issues. This is important because it shows that many patients thought to have GERD may not actually have it, highlighting the need for careful diagnosis and treatment options. Who this helps: This helps patients who suffer from reflux symptoms and may be misdiagnosed, as well as doctors looking for more accurate diagnoses.

Plain English
This study looked at how well Golimumab works for patients with ulcerative colitis (UC) over a long period of time in real-world settings in Italy. Out of 178 patients treated, only 32% achieved clinical remission after their treatment, and just 3.4% remained in remission after 42 months. While 36% had a clinical response and only a small number experienced adverse effects, the overall findings indicate that Golimumab struggles to maintain long-term remission for UC. Who this helps: This helps patients with ulcerative colitis and their doctors understand the long-term effectiveness of Golimumab in managing their condition.

Plain English
This study looked at how common a condition called symptomatic uncomplicated diverticular disease (SUDD) is among people who have diverticulosis. Researchers found that only 6.81% of patients with diverticulosis had SUDD, which is lower than what many had thought; additionally, 1.89% had post-diverticulitis SUDD, and 6.38% had symptoms similar to irritable bowel syndrome (IBS). Understanding the actual prevalence helps doctors better diagnose and treat patients with abdominal pain, especially as many may be experiencing IBS or other issues instead. Who this helps: This benefits patients and doctors by improving diagnosis and treatment options.

Plain English
This study investigated the impact of diet on diverticulosis—a common condition affecting the colon—and its complications. Researchers found that a high intake of red meat slightly increased the risk of acute diverticulitis, while higher consumption of poultry did not show any risk. Interestingly, eating fish may lower the risk of diverticulitis, but this effect varies when considering other dietary factors. Who this helps: Patients with diverticular disease or those concerned about diverticulitis.

Plain English
This study looked at the severity of diverticular disease in over 11,000 patients who underwent colonoscopy between 2012 and 2018. Researchers found that factors like being over 70 years old, having high blood pressure, and smoking increased the severity of the disease. Patients with severe diverticular disease required more hospital care, had longer stays, and incurred higher costs, while those with diverticulitis were less likely to also have colorectal cancer. Who this helps: This research benefits doctors and healthcare providers managing patients with diverticular disease.

Plain English
The study focused on a system called DICA, which helps doctors classify the severity of diverticular disease in the colon using videos of endoscopic examinations. Out of 66 endoscopists, they found that agreement on scoring was relatively high, with 81.3% agreement for severe cases (DICA 3) and moderate for less severe cases (70.2% for DICA 1). This consistency is important because it means doctors can reliably communicate the disease's severity, helping guide treatment decisions. Who this helps: Patients with diverticular disease benefit from more accurate assessments and better treatment planning.

Plain English
This study looked at diverticulosis, a common colon condition, and how inflammation affects the symptoms associated with it. Researchers found that about 20% of people with diverticulosis experience recurring abdominal pain, which is linked to low-grade inflammation in the gut. Understanding this connection is important because it could lead to better treatments for people with diverticulosis and help manage their symptoms more effectively. Who this helps: This helps patients with diverticulosis and their doctors.

Plain English
This study looked at how effective and safe the medication vedolizumab is for patients with ulcerative colitis and Crohn's disease treated in regular outpatient settings. Out of 136 patients, 63 (46.3%) achieved remission after 18 months, with 52.7% of ulcerative colitis patients and 33.3% of Crohn's patients improving significantly. It’s important because it shows that vedolizumab can help many patients manage their inflammatory bowel diseases effectively outside of specialized clinics, with only a small number experiencing serious side effects. Who this helps: Patients with ulcerative colitis and Crohn's disease.

Plain English
This study looked at the effectiveness and safety of a biosimilar drug called CT-P13 for treating inflammatory bowel disease (IBD) in patients at various Italian clinics. Among 141 patients, 57.3% with ulcerative colitis (UC) and 75.6% with Crohn's disease (CD) achieved remission after an average follow-up of 24 months. The findings are significant because they indicate that CT-P13 works well and is safe for both new patients and those who switched from another infliximab treatment. Who this helps: Patients with inflammatory bowel disease.

Plain English
Researchers gathered doctors from 18 countries to share their knowledge about diverticulosis and diverticular disease, focusing on its causes, symptoms, and treatment options. They came up with 39 important statements that all participants agreed on, showing a 100% consensus on key points, which were voted on using a clear scale. This matters because it helps standardize understanding and treatment approaches for these common digestive conditions. Who this helps: This helps patients and healthcare providers by providing clear guidelines for managing diverticulosis and diverticular disease.

Plain English
This study examined the effectiveness of budesonide MMX in patients with diverticular disease who continued to have symptoms despite previous treatments. After 6 months, patients showed a large decrease in abdominal pain and other symptoms, with their level of fecal calprotectin (a marker of inflammation) dropping significantly from 244.5 to 51.0, indicating improved bowel health. These findings are important because they suggest budesonide MMX can provide relief for patients who don’t respond to standard therapies. Who this helps: This helps patients with diverticular disease who have not found relief from other medications.

Plain English
Researchers studied how well doctors agree on a scoring system called the DICA classification, which rates the severity of diverticulosis and diverticular disease. They found a high agreement rate of 91.8% among 96 doctors who scored a set of endoscopic videos, with DICA 2 and DICA 3 achieving even higher agreement rates of 96.5% and 99.5%, respectively. This is important because consistent scoring can improve diagnosis and treatment of these conditions, leading to better care for patients. Who this helps: This helps patients with diverticular disease and their doctors.

Plain English
This research focused on the best ways to diagnose diverticular disease, a condition that causes frequent abdominal pain. It found that while certain biomarkers like CRP and fecal calprotectin can be useful, colonoscopy remains the most reliable method for diagnosing the disease. Additionally, a new scoring system, the DICA classification, can help doctors assess the severity of the disease based on various observed parameters. Who this helps: This information benefits doctors and patients experiencing diverticular disease.